皮下注射达雷妥尤单抗联合泊马度胺和地塞米松对比泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者(APOLLO):一项开放标签、随机、多中心、3期试验的延长随访
APOLLO试验延长随访显示,在中位随访39.6个月时,达雷妥尤单抗联合泊马度胺和地塞米松组的中位总生存期为34.4个月,对照组为23.7个月,差异未达统计学显著(HR 0.82,95%CI 0.61-1.11;p=0.20)。长期安全性结果继续支持该联合方案用于复发或难治性多发性骨髓瘤。
要点
- 中位随访39.6个月,D-Pd组中位OS 34.4个月 vs Pd组23.7个月(HR 0.82,95%CI 0.61-1.11;p=0.20)。
- 3-4级治疗中出现的不良事件最常见为中性粒细胞减少(D-Pd组69% vs Pd组51%)。
- 严重治疗中出现的不良事件D-Pd组54% vs Pd组40%,最常见为肺炎(15% vs 9%)。
核心结论
- 尽管两组间观察到的总生存差异未达统计学显著,长期随访的安全性结果继续支持达雷妥尤单抗联合泊马度胺和地塞米松用于复发或难治性多发性骨髓瘤患者。
研究设计与样本
- APOLLO为开放标签、随机、3期试验,在欧洲12个国家的48个学术中心和医院开展。
- 纳入年龄≥18岁、ECOG体能状态评分0-2、既往接受过至少一线治疗(包括来那度胺和蛋白酶体抑制剂)、对至少一线抗骨髓瘤治疗达部分缓解或更好、且若仅接受过一线治疗则需对来那度胺难治的复发或难治性多发性骨髓瘤成人患者。
- 采用交互式网络应答系统按1:1随机分配至达雷妥尤单抗联合泊马度胺和地塞米松组或泊马度胺和地塞米松组,按既往治疗线数和国际分期系统疾病分期分层。
- 2017年6月22日至2019年6月13日期间共随机分配304例患者:151例至达雷妥尤单抗联合泊马度胺和地塞米松组,153例至泊马度胺和地塞米松组。
- 中位年龄67岁(IQR 60-72);143例(47%)为女性,161例(53%)为男性,272例(89%)为白人。
主要发现
- 在中位随访39.6个月(IQR 37.1-43.7)时,达雷妥尤单抗联合泊马度胺和地塞米松组的中位总生存期为34.4个月(95%CI 23.7-40.3),泊马度胺和地塞米松组为23.7个月(95%CI 19.6-29.4)(HR 0.82,95%CI 0.61-1.11;p=0.20)。
- 最常见的3-4级治疗中出现的不良事件为中性粒细胞减少(达雷妥尤单抗联合泊马度胺和地塞米松组149例中103例[69%] vs 泊马度胺和地塞米松组150例中76例[51%])、贫血(27例[18%] vs 32例[21%])和血小板减少(27例[18%] vs 28例[19%])。
- 严重治疗中出现的不良事件在达雷妥尤单抗联合泊马度胺和地塞米松组149例中发生80例(54%),在泊马度胺和地塞米松组150例中发生60例(40%),最常见为肺炎(149例中23例[15%] vs 150例中13例[9%])。
- 导致死亡的治疗中出现的不良事件在达雷妥尤单抗联合泊马度胺和地塞米松组149例中发生13例(9%),在泊马度胺和地塞米松组150例中发生13例(9%);达雷妥尤单抗联合泊马度胺和地塞米松组有4例(3%)不良事件(151例中)在末次治疗剂量后30天内导致死亡且被认为与研究治疗相关(感染性休克[1例];脓毒症[1例];骨髓衰竭、弯曲杆菌感染和肝脏疾病[1例];肺炎[1例]),泊马度胺和地塞米松组无此类事件。
关键数值与推荐
- 达雷妥尤单抗给药方案:皮下注射1800 mg或静脉注射16 mg/kg,第1-2周期每周一次,第3-6周期每2周一次,此后每4周一次。
- 泊马度胺4 mg口服每日一次,第1-21天;地塞米松40 mg口服每日一次,第1、8、15、22天;28天为一周期,直至疾病进展或不可接受的毒性。
临床怎么用
- 原文结论指出,尽管总生存差异未达统计学显著,长期随访的安全性结果继续支持达雷妥尤单抗联合泊马度胺和地塞米松用于复发或难治性多发性骨髓瘤患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The primary analysis of the APOLLO trial, done after a median follow-up of 16·9 months, showed that daratumumab plus pomalidomide and dexamethasone significantly improved progression-free survival versus pomalidomide and dexamethasone. Here, we report the final overall survival and updated safety results from APOLLO. METHODS: APOLLO was an open-label, randomised, phase 3 trial conducted at 48 academic centres and hospitals across 12 countries in Europe, that included adults aged 18 years or older with relapsed or refractory multiple myeloma who had an ECOG performance status score of 0-2, had received at least one previous line of therapy, including lenalidomide and a proteasome inhibitor, had a partial response or better to one or more previous lines of antimyeloma therapy, and were refractory to lenalidomide if they had received only one previous line of therapy. An interactive web-response system was used to randomly assign patients (1:1) to receive daratumumab plus pomalidomide and dexamethasone or pomalidomide and dexamethasone; patients were stratified by the number of previous lines of therapy and International Staging System disease stage. Oral pomalidomide (4 mg once daily; days 1-21) and dexamethasone (40 mg once daily; days 1, 8, 15, and 22) were given in 28-day cycles until disease progression or unacceptable toxicity. Daratumumab (1800 mg subcutaneously or 16 mg/kg intravenously) was administered weekly (cycles 1-2), every 2 weeks (cycles 3-6), and every 4 weeks thereafter. The primary endpoint of progression-free survival, which has previously been reported, and the pre-planned secondary endpoint of overall survival were assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT03180736) and is no longer enrolling patients. FINDINGS: Between June 22, 2017, and June 13, 2019, 304 patients were randomly assigned: 151 to the daratumumab plus pomalidomide and dexamethasone group and 153 to the pomalidomide and dexamethasone group. The median age was 67 years (IQR 60-72); 143 (47%) patients were female and 161 (53%) were male, and 272 (89%) were White. At a median follow-up of 39·6 months (IQR 37·1-43·7), median overall survival was 34·4 months (95% CI 23·7-40·3) in the daratumumab plus pomalidomide and dexamethasone group versus 23·7 months (19·6-29·4) in the pomalidomide and dexamethasone group (hazard ratio [HR] 0·82 [95% CI 0·61-1·11]; p=0·20). The most common grade 3-4 treatment-emergent adverse events were neutropenia (103 [69%] of 149 with daratumumab plus pomalidomide and dexamethasone vs 76 [51%] of 150 with pomalidomide and dexamethasone), anaemia (27 [18%] vs 32 [21%]), and thrombocytopenia (27 [18%] vs 28 [19%]). Serious treatment-emergent adverse events occurred in 80 (54%) of 149 patients in the daratumumab plus pomalidomide and dexamethasone group and in 60 (40%) of 150 patients in the pomalidomide and dexamethasone group, the most common of which was pneumonia (23 [15%] of 149 vs 13 [9%] of 150). Treatment-emergent adverse events resulting in death occurred in 13 (9%) of 149 patients in the daratumumab plus pomalidomide and dexamethasone group and in 13 (9%) of 150 patients in the pomalidomide and dexamethasone group, with 4 (3%) of 151 adverse events leading to death within 30 days of the last treatment dose thought to be related to study treatment in the daratumumab plus pomalidomide and dexamethasone group (septic shock [n=1]; sepsis [n=1]; bone marrow failure, campylobacter infection, and liver disorder [n=1]; and pneumonia [n=1]) and none in the pomalidomide and dexamethasone group. INTERPRETATION: Although the difference in overall survival observed between treatment groups was not significant, the safety profile results with long-term follow-up reported here continue to support the use of daratumumab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. FUNDING: European Myeloma Network and Janssen Research & Development.
引用
- Dimopoulos MA, Terpos E, Boccadoro M, et al. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023. PMID: 37793772. doi:10.1016/S2352-3026(23)00218-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。